Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.75 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.75 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.75 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.75 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.75 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.75 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.75 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.75 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.75 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.75 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.75 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.75 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd2461 SCHEMBL29360368 | 1.00 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| Azd2461 SCHEMBL29361302 | 1.00 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL22852674 | 0.97 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL22852672 | 0.95 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL31311843 | 0.92 | PARP1 (0.85) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL76871 | 0.91 | PARP1 (0.84) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL87500 | 0.91 | PARP1 (0.84) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL22852677 | 0.91 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL78156 | 0.91 | PARP1 (0.83) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL86912 | 0.91 | PARP1 (0.82) | PARP1PRAP1TNKSADORA1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | claimed |
| US-11191770-B2 | — | — | 2021-12-07 | — | — | US | claimed |
| CN-112334133-A | Quinolone analogs and salts thereof, compositions, and methods of use thereof | 生华生物科技股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| WO-2019168688-A9 | QUINOLONE ANALOGS AND THEIR SALTS, COMPOSITIONS, AND METHOD FOR THEIR USE | SENHWA BIOSCIENCES, INC. (TW) | 2019-11-14 | — | — | WO | claimed |
| US-20190224209-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2019-07-25 | — | — | US | claimed |
| US-20110015393-A1 | PHTHALAZINONE COMPOUND | ASTRAZENECA AB (SE) | 2011-01-20 | — | — | US | claimed |
| WO-2011007145-A1 | PHTHALAZINONE COMPOUND AS PARP INHIBITOR | ASTRAZENECA AB (SE) | 2011-01-20 | — | — | WO | claimed |
| US-20250177474-A1 | PROTEIN INTERFACES | SYNTHEX, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-3377068-B1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2025-03-26 | — | — | EP | disclosed |
| US-12214008-B2 | Protein interfaces | SYNTHEX, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4269427-A2 | PROTEIN INTERFACES | Synthex, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4249072-A2 | CRYSTALLINE FORMS OF QUINOLONE ANALOGS AND THEIR SALTS | Senhwa Biosciences, Inc. (TW) | 2023-09-27 | — | — | EP | disclosed |
| EP-3463414-B1 | PROTEIN INTERFACES | SYNTHEX INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20110015393-A1 | PHTHALAZINONE COMPOUND | ASTRAZENECA AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015393-A1 | PHTHALAZINONE COMPOUND | ASTRAZENECA AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015393-A1 | PHTHALAZINONE COMPOUND | ASTRAZENECA AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015393-A1 | PHTHALAZINONE COMPOUND | ASTRAZENECA AB (SE) | 2011-01-20 | — | — | US | disclosed |
| EP-2231638-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191770-B2 | — | CXCR4, TLR7, CCR7 | PARP1 2554/4885PRAP1 2956/4885TNKS 2798/4885 |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | PARP1 1973/4885PRAP1 2633/4885TNKS 4458/4885 |
| US-20190224209-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | PARP1 1475/4885PRAP1 3629/4885TNKS 960/4885 |
| US-20110015393-A1 | PHTHALAZINONE COMPOUND | PML, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA4 | PARP1 237/4885PRAP1 518/4885TNKS 2597/4885 |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | PARP1 1475/4885PRAP1 3629/4885TNKS 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.